South San Francisco, CA based Crescendo Bioscience has announced study results which validate its Vectra DA blood test’s ability to predict how a patient will respond to treatment for rheumatoid arthritis (RA). Vectra DA tests for 12 biomarkers which are associated with RA, and uses a proprietary algorithm to assign a numerical score which can determine how a patient is responding to treatment.
From the product page:
Vectra DA was developed using a broad survey of RA biology, with serial studies to determine a final assay composed of biomarkers that robustly assess disease activity. Approximately 400 candidate biomarkers were chosen from an extensive screen of literature, databases, and experimental data that included gene expression, protein arrays, and biological pathways. Of those, 130 candidates were screened in clinical studies. Successive studies in >1,300 total patients with RA refined the biomarker set to those 12 with the greatest ability to evaluate RA disease activity, based on association with clinical measures including the DAS28CRP. A statistical algorithm was developed that used the biomarker levels to calculate a disease activity score. Evaluation of the algorithm in an independent patient cohort validated its ability to quantify RA disease activity.
Product page: Vectra DA…
